Clinical Trials Logo

Cicatrix clinical trials

View clinical trials related to Cicatrix.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06437912 Completed - Scar Clinical Trials

Effectiveness of Botulinum Toxin A in Preventing Scar Formation and Initial Exploration of "Optimal Concentration"

Start date: March 23, 2023
Phase: Early Phase 1
Study type: Interventional

Each year, millions of burn, trauma, or surgical patients worldwide suffer from scarring that severely affects their quality of life and social functioning. In order to prevent and treat diseases related to abnormal scar hyperplasia, clinicians and researchers have adopted various methods, such as scar grinding, surgical resection, drug injection in scar tissue, cryotherapy, laser and so on. However, these methods can not effectively inhibit the abnormal proliferation of scars and improve the adverse effects of existing scars on patients. To date, there is no accepted gold standard for the effective treatment and improvement of abnormal scar tissue.

NCT ID: NCT05839574 Completed - Clinical trials for Cesarean Scar Pregnancy

Letrozole add-on in the Treatment of Cesarean Scar Pregnancy

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

It is hypothesized that the inhibition of estradiol production by letrozole may interfere with physiological effects of progesterone necessary to maintain the pregnancy. There is no reference treatment of cesarean scar pregnancy (CSP) as the limited number of cases precludes the extrapolation of results. In our center we successfully use two-step treatment with methotrexate (MTX) followed by hysteroscopic removal of products of conception (POC). The time in between is needed to achieve a decrease in the trophoblast's vital potential (B-hCG fall) and its vascularization. Additional administration of letrozole could further reduce the vital potential of the pregnancy, eliminating the need for another dose of MTX, resulting in faster healing and lower rate of complications.

NCT ID: NCT05704114 Completed - Acne Vulgaris Clinical Trials

Tazarotene 0.045% Lotion for Treating PIE and PIH in Subjects With Acne

Start date: February 1, 2021
Phase: Phase 4
Study type: Interventional

The purpose of the study is to assess the safety and efficacy of Arazlo Lotion (Tazarotene 0.045% Lotion) for treatment of postinflammatory erythema and postinflammatory hyperpigmentation in subjects with acne.

NCT ID: NCT05691049 Completed - Clinical trials for Acne Scars - Mixed Atrophic and Hypertrophic

Evaluation of Efficacy and Safety of HCC_45 for the Correction of Acne Scars of the Face

Start date: November 24, 2022
Phase: N/A
Study type: Interventional

Acne scars represent a frequent complication of moderate/severe acne and may negatively impact on psychosocial and physical well-being of acne patients. Several types of acne scars have been classified and the same patient is likely to have more than one type. Each type can be treated with varying degrees of success. The main acne scars are the following: Atrophic or Depressed Scarring: - Ice pick: An ice pick scar has a wide shaft that narrows down to the tip. It resembles a hole that's wide at the top and narrows to a point as it goes deeper into the skin. Such an indentation is common and one of the most challenging scars to heal. This scar is more frequent on forehead and upper cheeks, where skin is thinner. - Rolling: These scars are typically found on the lower cheeks and jaw, where skin is thicker. The indents have sloping edges that makes the skin look uneven and wavy. - Boxcar: Boxcar scars are indents that have sharper edges. Those edges go down deep into the skin. These scars are common on the lower checks and jaw.

NCT ID: NCT05618912 Completed - Clinical trials for Patient Satisfaction

Scar Appearance After Postoperative Hydrocolloid Dressing Versus Standard Petrolatum Ointment

Start date: October 17, 2022
Phase: N/A
Study type: Interventional

Patients will be randomized either to receive standard daily dressing or hydrocolloid dressing using a randomization generator. After closing the wound with the sutures,the scar will be covered by a hydrocolloid dressing, which will be left in place for 7 days(Experimental) or the standard dressing (Control) that will be covered with petrolatum jelly and bandaging during this time period, which has to be re-applied daily. Patients and dermatologic surgeons will then complete surveys 7 days, 30 days, and 90 days after surgery to evaluate the cosmetic appearance of these scars.

NCT ID: NCT05412745 Completed - Keloid Clinical Trials

Class I Medical Device on Post-surgical Scars

Start date: May 1, 2022
Phase: N/A
Study type: Interventional

To compare the effect of a class I pullulan based medical device containing Allium cepa & HA versus a class I medical device silicone gel on new post-surgical wounds

NCT ID: NCT05386732 Completed - Acne Scarring Clinical Trials

Safety and Efficacy of the 4MD Micro Needling Device in the Treatment of Acne Scars

Start date: June 19, 2020
Phase:
Study type: Observational

The objective of this post market clinical follow-up study is to assess the safety and effectiveness of the 4MD microneedling device in reducing scarring of atrophic acne scars. The Primary endpoint was to show a reduction in acne scarring in accordance with the Acne Scar Assessment Scale as used by Skinpen (Bellus Medical (DEN160029)). Goodman and Baron and Jacob acne scar assessment and classification will also be utilized Safety endpoint: incidence of adverse events and side effects

NCT ID: NCT05355181 Completed - Back Pain Clinical Trials

Scar Mobilization Techniques vs Core Stability Exercises on Scar Tissue and Lumbopelvic Pain

Start date: April 20, 2022
Phase: N/A
Study type: Interventional

The study will be a Randomized clinical trial to check the effects of scar mobilization techniques with and without core stabilization exercises on scar tissue mobility and lumbopelvic pain in females after a cesarean section suffering from back pain and restricted scar mobility. Duration of study will 6 months, convenient sampling technique used, subject following eligibility criteria from Rafiqa Medical Centre, Sargodha and Fatima Hospital, Sargodha, will randomly be allocated in two groups via lottery method, baseline assessment will be done, Group A participants will be given baseline treatment along with scar mobilization and core stabilization exercises, Group B participants will be given baseline treatment along with scar mobilization for 3 weeks. On the 5th and 9th day, the post-intervention assessment will be done via, Manual Scar mobility testing, Vancouver Scar Scale, Numeric Pain Rating Scale, and Oswestry Disability Index. 3 sessions per week will be given.

NCT ID: NCT05271708 Completed - Scar Clinical Trials

Explore the Short- and Mid-term Effects of Fespixon in Scar Cosmesis Following Cervical or Abdominal Surgery

Start date: January 5, 2022
Phase: Phase 4
Study type: Interventional

The aim of this study is to evaluate the efficacy of the Fespixon cream for prevention and/or appearance reduction of different types of linear scars during the 12-week treatment phase, which is assessed by the blinded independent evaluator.

NCT ID: NCT05239351 Completed - Lipodystrophy Clinical Trials

Evaluating Performance and Safety of the Medical Device Jalucomplex in the Treatment of Facial and Neck Tissue Defects

Start date: March 7, 2022
Phase: N/A
Study type: Interventional

The Research Question of the present study is the following: in a population of men and women presenting facial and neck dermal tissue defects (scars, hypertrophic scars, depressed plaques, and lipodystrophy defects) will linear hyaluronic acid (Jalucomplex®) significantly decrease and / or improve their appearance, results observed after 4 and 8 weeks?